Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Crispr Therapeutics AG (CRSPN) AI Stock Analysis

MX:CRSPN

Crispr Therapeutics AG

(BMV:CRSPN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
CRISPR gene-editing platform and diversified pipelineA focused CRISPR/Cas9 platform applied across multiple therapeutic areas gives CRISPR Therapeutics a reusable scientific foundation rather than dependence on one candidate. A broader pipeline can create several paths to clinical advancement, partnerships and future commercialization over the next several quarters.
Negative Factors
Negative gross profit and substantial lossesNegative gross profit and large operating and net losses show that current economics do not yet support self-sustaining profitability. This limits internal funding for research and commercialization, increases dependence on financing or partners, and makes future earnings power highly dependent on clinical and commercial execution.

Crispr Therapeutics AG (CRSPN) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%MX:CRSPN-23.13%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
MXN 4.97B
Dividend Yield
―
Average Volume (3M)
173
Price to Earnings (P/E)
-10.8
Beta (1Y)
-0.11
Revenue Growth
-69.22%
EPS Growth
19.84%
Country
Mexico
Employees
393
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associat...

Crispr Therapeutics AG Risk Analysis

Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Crispr Therapeutics AG Peers Comparison

Overall Rating

Financial Indicators

MX:CRSPN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-30%-20%-10%0%MX:CRSPNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
MX:CRSPN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MX:CRSPNCrispr Therapeutics915.00-275.31-23.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.